Back to Newsroom

Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference

NORWOOD, MA — (Marketwired) — 06/08/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that safety, pharmacokinetic and efficacy data from the Phase 2 clinical study of anabasum (formerly known as JBT-101) for the treatment of cystic fibrosis will be presented at the European Cystic Fibrosis Society (“ECFS”) 2017 Conference, being held June 7-10, 2017 in Seville, Spain.
READ MORE…